IL1B and lung carcinoma: The mechanisms driving lung cancer due to fine PM are not primarily through increased genetic mutations but rather rely on altering the immune system, creating an inflammatory microenvironment, attracting macrophages to the lungs, and stimulating the release of IL-1β.